Evotec SE to Post FY2024 Earnings of ($0.10) Per Share, HC Wainwright Forecasts (NASDAQ:EVO)

Evotec SE (NASDAQ:EVO) – Equities research analysts at HC Wainwright issued their FY2024 earnings estimates for Evotec in a research note issued on Thursday, April 25th. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.10) per share for the year. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Evotec’s FY2025 earnings at $0.02 EPS, FY2026 earnings at $0.36 EPS and FY2027 earnings at $0.42 EPS.

A number of other brokerages have also weighed in on EVO. Royal Bank of Canada upgraded Evotec from a “sector perform” rating to an “outperform” rating in a research note on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised Evotec from a “hold” rating to a “buy” rating in a report on Friday, April 12th.

Evotec Trading Up 3.6 %

Shares of EVO opened at $5.20 on Monday. The firm’s 50-day simple moving average is $7.20 and its 200 day simple moving average is $8.58. Evotec has a 52 week low of $4.87 and a 52 week high of $13.49.

Institutional Investors Weigh In On Evotec

Institutional investors have recently made changes to their positions in the stock. Mubadala Investment Co PJSC bought a new position in shares of Evotec in the fourth quarter worth $53,931,000. Optiver Holding B.V. grew its stake in Evotec by 643.1% during the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after buying an additional 69,936 shares in the last quarter. Finally, Quadrant Capital Group LLC bought a new position in Evotec in the 4th quarter valued at about $25,000. 5.81% of the stock is currently owned by institutional investors.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.